JP5363655B2 - アンチセンス核酸 - Google Patents

アンチセンス核酸 Download PDF

Info

Publication number
JP5363655B2
JP5363655B2 JP2012531987A JP2012531987A JP5363655B2 JP 5363655 B2 JP5363655 B2 JP 5363655B2 JP 2012531987 A JP2012531987 A JP 2012531987A JP 2012531987 A JP2012531987 A JP 2012531987A JP 5363655 B2 JP5363655 B2 JP 5363655B2
Authority
JP
Japan
Prior art keywords
nucleic acid
exon
synthetic nucleic
antisense oligomer
oligomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012531987A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2012029986A1 (ja
Inventor
直樹 渡辺
洋平 佐藤
伸一 武田
哲也 永田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
National Center of Neurology and Psychiatry
Original Assignee
Nippon Shinyaku Co Ltd
National Center of Neurology and Psychiatry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45773054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5363655(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd, National Center of Neurology and Psychiatry filed Critical Nippon Shinyaku Co Ltd
Priority to JP2012531987A priority Critical patent/JP5363655B2/ja
Publication of JPWO2012029986A1 publication Critical patent/JPWO2012029986A1/ja
Application granted granted Critical
Publication of JP5363655B2 publication Critical patent/JP5363655B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
JP2012531987A 2010-09-01 2011-08-31 アンチセンス核酸 Active JP5363655B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012531987A JP5363655B2 (ja) 2010-09-01 2011-08-31 アンチセンス核酸

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010196032 2010-09-01
JP2010196032 2010-09-01
PCT/JP2011/070318 WO2012029986A1 (ja) 2010-09-01 2011-08-31 アンチセンス核酸
JP2012531987A JP5363655B2 (ja) 2010-09-01 2011-08-31 アンチセンス核酸

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013184193A Division JP6141728B2 (ja) 2010-09-01 2013-09-05 アンチセンス核酸

Publications (2)

Publication Number Publication Date
JPWO2012029986A1 JPWO2012029986A1 (ja) 2013-10-31
JP5363655B2 true JP5363655B2 (ja) 2013-12-11

Family

ID=45773054

Family Applications (12)

Application Number Title Priority Date Filing Date
JP2012531987A Active JP5363655B2 (ja) 2010-09-01 2011-08-31 アンチセンス核酸
JP2013184193A Active JP6141728B2 (ja) 2010-09-01 2013-09-05 アンチセンス核酸
JP2015256962A Active JP6193343B2 (ja) 2010-09-01 2015-12-28 アンチセンス核酸
JP2017154320A Active JP6465932B2 (ja) 2010-09-01 2017-08-09 アンチセンス核酸
JP2019001091A Active JP6647430B2 (ja) 2010-09-01 2019-01-08 アンチセンス核酸
JP2020003338A Active JP6867619B2 (ja) 2010-09-01 2020-01-14 アンチセンス核酸
JP2021008202A Active JP6867636B1 (ja) 2010-09-01 2021-01-21 アンチセンス核酸
JP2021008200A Active JP6867620B1 (ja) 2010-09-01 2021-01-21 アンチセンス核酸
JP2021008201A Active JP6867621B1 (ja) 2010-09-01 2021-01-21 アンチセンス核酸
JP2021058526A Pending JP2021104037A (ja) 2010-09-01 2021-03-30 アンチセンス核酸
JP2022209270A Pending JP2023036865A (ja) 2010-09-01 2022-12-27 アンチセンス核酸
JP2024145055A Pending JP2024170458A (ja) 2010-09-01 2024-08-27 アンチセンス核酸

Family Applications After (11)

Application Number Title Priority Date Filing Date
JP2013184193A Active JP6141728B2 (ja) 2010-09-01 2013-09-05 アンチセンス核酸
JP2015256962A Active JP6193343B2 (ja) 2010-09-01 2015-12-28 アンチセンス核酸
JP2017154320A Active JP6465932B2 (ja) 2010-09-01 2017-08-09 アンチセンス核酸
JP2019001091A Active JP6647430B2 (ja) 2010-09-01 2019-01-08 アンチセンス核酸
JP2020003338A Active JP6867619B2 (ja) 2010-09-01 2020-01-14 アンチセンス核酸
JP2021008202A Active JP6867636B1 (ja) 2010-09-01 2021-01-21 アンチセンス核酸
JP2021008200A Active JP6867620B1 (ja) 2010-09-01 2021-01-21 アンチセンス核酸
JP2021008201A Active JP6867621B1 (ja) 2010-09-01 2021-01-21 アンチセンス核酸
JP2021058526A Pending JP2021104037A (ja) 2010-09-01 2021-03-30 アンチセンス核酸
JP2022209270A Pending JP2023036865A (ja) 2010-09-01 2022-12-27 アンチセンス核酸
JP2024145055A Pending JP2024170458A (ja) 2010-09-01 2024-08-27 アンチセンス核酸

Country Status (20)

Country Link
US (16) US9079934B2 (OSRAM)
EP (6) EP4403632A3 (OSRAM)
JP (12) JP5363655B2 (OSRAM)
KR (1) KR101310569B1 (OSRAM)
CN (1) CN103154245B (OSRAM)
AU (1) AU2011296882B2 (OSRAM)
CA (1) CA2809637C (OSRAM)
CY (2) CY1117367T1 (OSRAM)
DK (2) DK2612917T3 (OSRAM)
ES (2) ES2567411T3 (OSRAM)
HR (2) HRP20160336T1 (OSRAM)
HU (2) HUE027321T2 (OSRAM)
LT (1) LT3018211T (OSRAM)
PL (2) PL2612917T3 (OSRAM)
PT (1) PT3018211T (OSRAM)
RS (2) RS59361B1 (OSRAM)
SI (2) SI3018211T1 (OSRAM)
SM (2) SMT201900559T1 (OSRAM)
TW (1) TWI541024B (OSRAM)
WO (1) WO2012029986A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021182517A1 (ja) 2020-03-11 2021-09-16 隆光 矢野 －１フレームシフトを誘導するための１本鎖核酸分子及び組成物

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1766010T3 (pl) 2004-06-28 2011-07-29 Univ Western Australia Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
USRE48960E1 (en) 2004-06-28 2022-03-08 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
EP1855694B1 (en) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Antisense composition for treating muscle atrophy
CN101896186A (zh) 2007-10-26 2010-11-24 莱顿教学医院 对抗肌肉病症的方式和方法
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
SMT201900159T1 (it) 2008-10-24 2019-05-10 Sarepta Therapeutics Inc Composizioni di salto di esone per dmd
KR20230137491A (ko) 2009-11-12 2023-10-04 더 유니버시티 오브 웨스턴 오스트레일리아 안티센스 분자 및 이를 이용한 질환 치료방법
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
BR112014018427B1 (pt) * 2012-01-27 2021-11-03 Biomarin Technologies B.V. Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker
EP2935584A1 (en) * 2012-12-20 2015-10-28 Sarepta Therapeutics, Inc. Improved exon skipping compositions for treating muscular dystrophy
KR20240094032A (ko) 2013-03-14 2024-06-24 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이영양증의 치료를 위한 엑손 스키핑 조성물
NZ631245A (en) * 2013-03-14 2017-09-29 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy
HK1220154A1 (zh) 2013-03-15 2017-04-28 Sarepta Therapeutics, Inc. 改进的用於治疗肌营养不良的组合物
SG11201607095RA (en) * 2014-03-12 2016-10-28 Nippon Shinyaku Co Ltd Antisense nucleic acids
US10174319B2 (en) 2014-05-19 2019-01-08 Knc Laboratories Co., Ltd. Nucleic acid drug for inducing skipping of variant exon of CD44 gene and increasing expression of normal type CD44 mRNA
CN111575282B (zh) * 2014-06-17 2024-05-14 日本新药株式会社 反义核酸
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
CN108026531B (zh) * 2015-09-15 2021-09-14 日本新药株式会社 反义核酸
JP6875684B2 (ja) * 2015-09-16 2021-05-26 日本新薬株式会社 筋萎縮症治療用アンチセンス核酸
NZ781029A (en) 2015-10-09 2025-07-25 Wave Life Sciences Ltd Oligonucleotide compositions and methods thereof
EP3359668A4 (en) 2015-10-09 2019-06-05 Sarepta Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATING DUCHENNE MUSCLE DYSTROPHY AND ASSOCIATED ILLNESSES THEREOF
FR3044926B1 (fr) 2015-12-09 2020-01-31 Genethon Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
KR101686379B1 (ko) 2016-02-05 2016-12-13 박정열 휴대용 구이기
WO2017205879A2 (en) * 2016-05-24 2017-11-30 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
WO2017205496A1 (en) 2016-05-24 2017-11-30 Sarepta Therapeutics, Inc. Processes for preparing oligomers
MA45183A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MA45362A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
DK3464306T3 (da) 2016-05-24 2024-05-21 Sarepta Therapeutics Inc Fremgangsmåder til fremstilling af phosphorodiamidat-morpholino-oligomerer
KR20190024977A (ko) 2016-06-30 2019-03-08 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머
KR102824513B1 (ko) * 2016-07-05 2025-06-25 바이오마린 테크놀로지스 비.브이. 유전적 장애 치료를 위한, 특징이 개선된, 비사이클릭 스캐폴드 모이어티를 포함하는 프리-mrna 스플라이스 스위칭 또는 조정 올리고뉴클레오티드
KR101715572B1 (ko) 2016-10-11 2017-03-22 박종찬 구이대 승강구조를 갖는 양방향 구이기
BR112019012664A2 (pt) 2016-12-19 2020-01-21 Sarepta Therapeutics Inc conjugados de oligômero de salto de éxon para distrofia muscular
SG10202012839TA (en) 2016-12-19 2021-01-28 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
MD3554554T2 (ro) 2016-12-19 2022-12-31 Sarepta Therapeutics Inc Conjugați de oligomeri de omitere a exonului, pentru distrofie musculară
WO2018223056A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
CA3073736A1 (en) * 2017-08-31 2019-03-07 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
JP2020536057A (ja) 2017-09-28 2020-12-10 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーを処置するための併用療法
EP3784248A4 (en) * 2018-04-26 2022-08-10 Sarepta Therapeutics, Inc. EXON-SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
AU2019265904A1 (en) * 2018-05-11 2020-11-12 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US10758629B2 (en) 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
MY209148A (en) * 2018-06-26 2025-06-24 Nippon Shinyaku Co Ltd Composition comprising antisense oligonucleotide and use thereof for treatment of duchenne muscular dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
CN113453723A (zh) 2018-12-07 2021-09-28 牛津大学科技创新有限公司 接头
JP7185239B2 (ja) * 2018-12-25 2022-12-07 国立研究開発法人国立精神・神経医療研究センター 随時尿中細胞を用いた筋系細胞の誘導方法
GB201821269D0 (en) * 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
KR20220122673A (ko) 2019-12-26 2022-09-02 니뽄 신야쿠 가부시키가이샤 엑손 50의 스키핑을 유도하는 안티센스 핵산
JPWO2021172498A1 (OSRAM) 2020-02-28 2021-09-02
WO2022059754A1 (ja) * 2020-09-18 2022-03-24 天野エンザイム株式会社 加工ひよこ豆ミルクの製造方法
CA3211038A1 (en) 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
KR20240004609A (ko) 2021-04-30 2024-01-11 사렙타 쎄러퓨틱스 인코퍼레이티드 근이영양증에 대한 치료 방법
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
EP4366784A1 (en) 2021-07-09 2024-05-15 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US20240390508A1 (en) 2021-08-21 2024-11-28 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
WO2023027125A1 (ja) 2021-08-24 2023-03-02 ペプチドリーム株式会社 ヒトトランスフェリンレセプター結合抗体－ペプチドコンジュゲート
US20250066396A1 (en) 2021-12-27 2025-02-27 Nippon Shinyaku Co., Ltd. Method for producing oligonucleic acid compound
EP4215614A1 (en) 2022-01-24 2023-07-26 Dynacure Combination therapy for dystrophin-related diseases
EP4486386A1 (en) 2022-03-03 2025-01-08 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
JP2025079347A (ja) * 2022-03-11 2025-05-22 日本新薬株式会社 キャリアペプチドが連結された核酸
EP4493693A1 (en) 2022-03-17 2025-01-22 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer conjugates
US20250297253A1 (en) 2022-05-06 2025-09-25 Josho Gakuen Educational Foundation Artificial rna molecule
WO2025153061A1 (zh) * 2024-01-19 2025-07-24 云合智药（苏州）生物科技有限公司 用于抑制激活素iib型受体基因表达的核酸及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002010790A (ja) * 2000-04-26 2002-01-15 Masafumi Matsuo デュシェンヌ型筋ジストロフィー治療剤
WO2008036127A2 (en) * 2006-05-10 2008-03-27 Avi Biopharma, Inc. Oligonucleotide analogs having cationic intersubunit linkages
WO2010048586A1 (en) * 2008-10-24 2010-04-29 Avi Biopharma, Inc. Multiple exon skipping compositions for dmd
US20100168212A1 (en) * 2008-09-11 2010-07-01 Royal Holloway, University Of London Oligomers
WO2011057350A1 (en) * 2009-11-12 2011-05-19 The University Of Western Australia Antisense molecules and methods for treating pathologies

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0506830B1 (en) 1989-12-20 2005-12-14 Avi Biopharma, Inc. Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
JP2924179B2 (ja) 1993-02-19 1999-07-26 日本新薬株式会社 グリセロール誘導体，デバイス及び医薬組成物
US7321828B2 (en) 1998-04-13 2008-01-22 Isis Pharmaceuticals, Inc. System of components for preparing oligonucleotides
JP2000325085A (ja) 1999-05-21 2000-11-28 Masafumi Matsuo デュシェンヌ型筋ジストロフィー治療剤
AU5752601A (en) 2000-05-04 2001-11-12 Avi Biopharma Inc Splice-region antisense composition and method
US6727355B2 (en) 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
ITRM20020253A1 (it) 2002-05-08 2003-11-10 Univ Roma Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche.
CA3001404C (en) 2002-11-25 2020-07-28 Masafumi Matsuo Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
PL1766010T3 (pl) 2004-06-28 2011-07-29 Univ Western Australia Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
JP2006038608A (ja) 2004-07-27 2006-02-09 Tokyo Electric Power Co Inc:The 超音波検査装置及び方法
US20110046200A1 (en) 2004-08-03 2011-02-24 Michael T Howard Use of antisense oligonucleotides to effect translation modulation
FR2874384B1 (fr) 2004-08-17 2010-07-30 Genethon Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
EP1811024A1 (en) 2004-10-05 2007-07-25 Nippon Shinyaku Co., Ltd. Oligo double-stranded rna and medicinal composition
JP2006129594A (ja) 2004-10-28 2006-05-18 Hitachi Ltd 船舶用電気推進装置の制御方法及びその装置
KR20080031164A (ko) 2005-04-22 2008-04-08 아카데미슈 지켄후이스 라이덴 ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절
US20090069260A1 (en) 2005-05-30 2009-03-12 Nippon Shinyaku Co., Ltd Method for producing a nucleic-acid-containing complex preparation
EP3470072A1 (en) * 2005-06-23 2019-04-17 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
JP4816396B2 (ja) 2006-10-12 2011-11-16 富士ゼロックス株式会社 画像形成装置
WO2008096690A1 (ja) 2007-02-05 2008-08-14 Nippon Shinyaku Co., Ltd. ポリエチレングリコール誘導体
CN101896186A (zh) 2007-10-26 2010-11-24 莱顿教学医院 对抗肌肉病症的方式和方法
CA2704261C (en) 2007-11-15 2015-05-26 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
DK2607484T3 (en) 2008-10-27 2016-03-07 Biomarin Technologies B V Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-MRNA
JP2010196032A (ja) 2009-01-29 2010-09-09 Fujifilm Corp 水不溶性色材の分散体及びこの製造方法、これを用いた記録液、インクセット、印画物、画像形成方法、及び画像形成装置
CA2759899A1 (en) 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
KR20120093138A (ko) * 2009-06-17 2012-08-22 콜드스프링하버러보러토리 대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
CN103501793A (zh) 2011-02-08 2014-01-08 夏洛特-梅克伦堡医院(商业用名:卡罗来纳保健系统) 反义寡核苷酸
JP6478632B2 (ja) 2011-05-05 2019-03-06 サレプタ セラピューティクス， インコーポレイテッド ペプチドオリゴヌクレオチドコンジュゲート
BR112014018427B1 (pt) 2012-01-27 2021-11-03 Biomarin Technologies B.V. Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker
CN110257379B (zh) 2012-07-03 2023-08-11 马林生物科技有限公司 用于治疗肌肉萎缩症患者的寡核苷酸
EP2935584A1 (en) 2012-12-20 2015-10-28 Sarepta Therapeutics, Inc. Improved exon skipping compositions for treating muscular dystrophy
NZ631245A (en) 2013-03-14 2017-09-29 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy
KR20240094032A (ko) 2013-03-14 2024-06-24 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이영양증의 치료를 위한 엑손 스키핑 조성물
HK1220154A1 (zh) 2013-03-15 2017-04-28 Sarepta Therapeutics, Inc. 改进的用於治疗肌营养不良的组合物
US10112977B2 (en) 2014-06-23 2018-10-30 Toagosei Co., Ltd. Peptide for inducing multinucleation in cells, and use therefor
EP3572516B1 (en) 2014-08-09 2024-11-20 The Research Institute at Nationwide Children's Hospital Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene
JP2018529715A (ja) 2015-09-30 2018-10-11 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーを処置するための方法
EP3359668A4 (en) 2015-10-09 2019-06-05 Sarepta Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATING DUCHENNE MUSCLE DYSTROPHY AND ASSOCIATED ILLNESSES THEREOF
WO2017205496A1 (en) 2016-05-24 2017-11-30 Sarepta Therapeutics, Inc. Processes for preparing oligomers
MA45183A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
WO2017205879A2 (en) 2016-05-24 2017-11-30 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
DK3464306T3 (da) 2016-05-24 2024-05-21 Sarepta Therapeutics Inc Fremgangsmåder til fremstilling af phosphorodiamidat-morpholino-oligomerer
US20190275072A1 (en) 2016-05-24 2019-09-12 Sarepta Therapeutics, Inc. Pharmaceutical compositions comprising eteplirsen
KR20190024977A (ko) 2016-06-30 2019-03-08 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머
AU2017361784B2 (en) 2016-11-16 2021-07-15 Academisch Ziekenhuis Leiden Substances for targeting various selected organs or tissues
BR112019012664A2 (pt) 2016-12-19 2020-01-21 Sarepta Therapeutics Inc conjugados de oligômero de salto de éxon para distrofia muscular
SG10202012839TA (en) 2016-12-19 2021-01-28 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
MD3554554T2 (ro) 2016-12-19 2022-12-31 Sarepta Therapeutics Inc Conjugați de oligomeri de omitere a exonului, pentru distrofie musculară
CA3073736A1 (en) 2017-08-31 2019-03-07 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
JP2020536057A (ja) 2017-09-28 2020-12-10 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーを処置するための併用療法
EP3687577A1 (en) 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
JP2020536060A (ja) 2017-09-28 2020-12-10 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーを処置するための併用療法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002010790A (ja) * 2000-04-26 2002-01-15 Masafumi Matsuo デュシェンヌ型筋ジストロフィー治療剤
WO2008036127A2 (en) * 2006-05-10 2008-03-27 Avi Biopharma, Inc. Oligonucleotide analogs having cationic intersubunit linkages
US20100168212A1 (en) * 2008-09-11 2010-07-01 Royal Holloway, University Of London Oligomers
WO2010048586A1 (en) * 2008-10-24 2010-04-29 Avi Biopharma, Inc. Multiple exon skipping compositions for dmd
WO2011057350A1 (en) * 2009-11-12 2011-05-19 The University Of Western Australia Antisense molecules and methods for treating pathologies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6011052124; ＰＯＰＰＬＥＷＥＬＬ，　Ｌ．Ｊ．　ｅｔ　ａｌ．: 'Ｄｅｓｉｇｎ　ｏｆ　ｐｈｏｓｐｈｏｒｏｄｉａｍｉｄａｔｅ　ｍｏｒｐｈｏｌｉｎｏ　ｏｌｉｇｏｍｅｒｓ　（ＰＭＯｓ）　ｆｏｒ　ｔｈｅ　ｉｎｄｕｃｔｉｏｎ　ｏｆ　ｅｘｏｎ　ｓｋｉｐｐｉｎｇ　ｏｆ　ｔｈｅ　ｈ' Ｍｏｌ．　Ｔｈｅｒ． Ｖｏｌ．１７　Ｎｏ．３, 2009, ｐ．５５４-５６１ *
JPN6011052126; ＰＯＰＰＬＥＷＥＬＬ，　Ｌ．Ｊ．　ｅｔ　ａｌ．: 'Ｃｏｍｐａｒａｔｉｖｅ　ａｎａｌｙｓｉｓ　ｏｆ　ａｎｔｉｓｅｎｓｅ　ｏｌｉｇｏｎｕｃｌｅｏｔｉｄｅ　ｓｅｑｕｅｎｃｅｓ　ｔａｒｇｅｔｉｎｇ　ｅｘｏｎ　５３　ｏｆ　ｔｈｅ　ｈｕｍａｎ　ＤＭＤ　ｇｅｎｅ：' Ｎｅｕｒｏｍｕｓｃｕｌ．　Ｄｉｓｏｒｄ． Ｖｏｌ．２０　Ｎｏ．２, 201002, ｐ．１０２-１１０ *
JPN6011052128; ＡＡＲＴＳＭＡ-ＲＵＳ，　Ａ．　ｅｔ　ａｌ．: 'Ｔａｒｇｅｔｅｄ　ｅｘｏｎ　ｓｋｉｐｐｉｎｇ　ａｓ　ａ　ｐｏｔｅｎｔｉａｌ　ｇｅｎｅ　ｃｏｒｒｅｃｔｉｏｎ　ｔｈｅｒａｐｙ　ｆｏｒ　Ｄｕｃｈｅｎｎｅ　ｍｕｓｃｕｌａｒ　ｄｙｓｔｒｏｐｈｙ．' Ｎｅｕｒｏｍｕｓｃｕｌ．　Ｄｉｓｏｒｄ． Ｖｏｌ．１２　Ｓｕｐｐｌｅｍｅｎｔ, 2002, ｐ．Ｓ７１-Ｓ７７ *
JPN6011052130; ＷＩＬＴＯＮ，　Ｓ．Ｄ．　ｅｔ　ａｌ．: 'Ｍｏｌ．　Ｔｈｅｒ．' Ａｎｔｉｓｅｎｓｅ　ｏｌｉｇｏｎｕｃｌｅｏｔｉｄｅ-ｉｎｄｕｃｅｄ　ｅｘｏｎ　ｓｋｉｐｐｉｎｇ　ａｃｒｏｓｓ　ｔｈｅ　ｈｕｍａｎ　ｄｙｓｔｒｏｐｈｉｎ　ｇｅｎｅ　ｔｒａｎｓｃｒｉｐｔ． Ｖｏｌ．１５　Ｎｏ．７, 2007, ｐ．１２８８-１２９６ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021182517A1 (ja) 2020-03-11 2021-09-16 隆光 矢野 －１フレームシフトを誘導するための１本鎖核酸分子及び組成物

Also Published As

Publication number Publication date
US20200115411A1 (en) 2020-04-16
KR20130069762A (ko) 2013-06-26
US20230151050A1 (en) 2023-05-18
US20210284680A1 (en) 2021-09-16
TW201215408A (en) 2012-04-16
PT3018211T (pt) 2019-10-28
US10329319B2 (en) 2019-06-25
HUE046364T2 (hu) 2020-02-28
US20250042933A1 (en) 2025-02-06
HRP20191770T1 (hr) 2019-12-27
SI2612917T1 (sl) 2016-05-31
RS59361B1 (sr) 2019-11-29
JP2021104037A (ja) 2021-07-26
US10385092B2 (en) 2019-08-20
RS54649B1 (sr) 2016-08-31
DK2612917T3 (en) 2016-04-18
JP2016104021A (ja) 2016-06-09
JP2021072820A (ja) 2021-05-13
EP3018211A1 (en) 2016-05-11
SMT201600111B (it) 2016-07-01
EP2612917A4 (en) 2014-12-31
EP3581655A1 (en) 2019-12-18
AU2011296882B2 (en) 2015-04-09
JP6867619B2 (ja) 2021-04-28
US20190211050A1 (en) 2019-07-11
JP2019062913A (ja) 2019-04-25
US20190211049A1 (en) 2019-07-11
JP6193343B2 (ja) 2017-09-06
US20190315796A1 (en) 2019-10-17
JP2018027083A (ja) 2018-02-22
HUE027321T2 (en) 2016-10-28
US20190218244A1 (en) 2019-07-18
RU2567664C2 (ru) 2015-11-10
US20150166995A1 (en) 2015-06-18
US20200109162A1 (en) 2020-04-09
US9708361B2 (en) 2017-07-18
JP2021072822A (ja) 2021-05-13
JP2021072821A (ja) 2021-05-13
CY1117367T1 (el) 2017-04-26
JP6867620B1 (ja) 2021-04-28
US11028122B1 (en) 2021-06-08
KR101310569B1 (ko) 2013-09-23
PL3018211T3 (pl) 2020-02-28
EP3018211B1 (en) 2019-08-07
LT3018211T (lt) 2019-10-25
HRP20160336T1 (hr) 2016-04-22
US9079934B2 (en) 2015-07-14
CN103154245A (zh) 2013-06-12
US10683322B2 (en) 2020-06-16
JP2020072724A (ja) 2020-05-14
CA2809637A1 (en) 2012-03-08
JPWO2012029986A1 (ja) 2013-10-31
WO2012029986A1 (ja) 2012-03-08
EP2612917B1 (en) 2016-02-24
EP2612917A1 (en) 2013-07-10
CY1122167T1 (el) 2020-11-25
EP4400168A2 (en) 2024-07-17
US10647741B2 (en) 2020-05-12
US10662217B2 (en) 2020-05-26
US20170320903A1 (en) 2017-11-09
PL2612917T3 (pl) 2016-07-29
CA2809637C (en) 2018-06-05
JP6867621B1 (ja) 2021-04-28
SI3018211T1 (sl) 2019-11-29
EP4403632A3 (en) 2024-10-23
TWI541024B (zh) 2016-07-11
DK3018211T3 (da) 2019-10-14
JP6141728B2 (ja) 2017-06-07
AU2011296882A1 (en) 2013-04-18
US20210179659A1 (en) 2021-06-17
EP3543341A1 (en) 2019-09-25
US20210198306A1 (en) 2021-07-01
CN103154245B (zh) 2016-06-01
JP2023036865A (ja) 2023-03-14
US10487106B2 (en) 2019-11-26
JP2024170458A (ja) 2024-12-10
US20210340171A1 (en) 2021-11-04
EP4403632A2 (en) 2024-07-24
JP6465932B2 (ja) 2019-02-06
JP6867636B1 (ja) 2021-04-28
SMT201900559T1 (it) 2019-11-13
US10407461B2 (en) 2019-09-10
US10870676B2 (en) 2020-12-22
US20200102343A1 (en) 2020-04-02
JP2014054250A (ja) 2014-03-27
RU2013114396A (ru) 2014-10-10
JP6647430B2 (ja) 2020-02-14
US20130211062A1 (en) 2013-08-15
ES2750748T3 (es) 2020-03-27
ES2567411T3 (es) 2016-04-22
EP4400168A3 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
JP6867621B1 (ja) アンチセンス核酸
JP6701139B2 (ja) アンチセンス核酸
JP6384845B2 (ja) アンチセンス核酸
EP3118311A1 (en) Antisense nucleic acid

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130905

R150 Certificate of patent or registration of utility model

Ref document number: 5363655

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250